Over-expression of CXCR2 also predicted a poor OS and disease-free survival (DFS) in patients with high-grade serous ovarian cancer.[20] In gastric cancer,[38] researchers reported that patients with increased expression of GRO-α together with its receptor CXCR2 was significantly correlated with tumor progression and with more advanced TNM stages, and concordantly, patients with lower GRO-α and CXCR2 expressions had a relative better prognosis. This evidence concerns the gene CXCL1 and ovarian serous adenocarcinoma.